Market Research Report

Product code

990082

Global Cell and Gene Therapy Market: Focus on Product Type, Therapeutic Class, Pipeline, Regional and Country Data (15 Countries) - Analysis and Forecast, 2021-2027

Published: February 18, 2021 |

BIS Research Inc. | 285 Pages | Delivery time: 1-2 business days

Price

Description
Table of Contents
List of Tables

Add to Compare

"Global Cell and Gene Therapy Market to Grow at a CAGR of 33.82% from 2021-2027."

Market Report Coverage - Cell and Gene Therapy

Market Segmentation

By Product Type: Yescarta, Provenge, Luxtura, Kymriah, Imlygic, Gintuit, MACI, Laviv, Gendicine, Oncorine, Neovasculgen, Strimvelis, Invossa, Zolgenesma, Tecartus, Liso-Cel, Zyntelego, Others

By Therapeutic Class: Rare Diseases, Oncology, Hematology, Cardiovascular, Ophthalmology, Neurology and Other Therapeutic Classes

By Region: North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World

Regional Segmentation

North America - U.S., Canada

Europe - Germany, France, Italy, U.K., Spain,The Netherlands, Russia, and Rest-of-Europe

Asia-Pacific - China, Japan, India, Singapore, Australia, South Korea and Rest-of-Asia-Pacific (RoAPAC)

Latin America - Brazil, Mexico, and Rest-of-the-Latin America

Rest-of-the-World

Growth Drivers

Increasing Incidences of Cancer and other Chronic Diseases

Rising Number of Clinical Trials

Increasing Funding and Investments in Cell and Gene Therapy Market

Favorable Regulatory Environment and FDA Approvals for Cell and Gene Therapy Products

Market Challenges

Lack of Reliable Vector Production for Cell and Gene Therapy

Complex Manufacturing and Distribution Setup

Tedious Process of Therapeutic Commercialization

Market Opportunities

Drug Approvals and Strong Pipeline of Cell and Gene Therapies

Increasing Number of Mergers and Acquisitions within the Cell and Gene Industry

Key Cell and Gene Therapy Companies Profiled:

Amgen Inc., bluebird bio, Inc., Castle Creek Pharmaceutical Holdings., Kite Pharma, Inc., Novartis AG, Orchard Therapeutics plc., Pfizer, Inc., Spark Therapeutics, Inc., Vericel Corporation, Dendreon Pharmaceuticals LLC., Human Stem Cells Institute, Kolon TissueGene, Inc., Organogenesis Holdings Inc., Pfizer, Inc., RENOVA THERAPEUTICS, Shanghai Sunway Biotech Co. Ltd., and Sibiono GeneTech Co. Ltd.

Key Questions Answered in this Report:

What are the different types of approved cell and gene therapies available in the respective market?

What are the key development strategies implemented by the key players to stand out in this market?

What are the various manufacturing considerations within the cell and gene therapy market?

How have the strategic collaborations among the key players providing a push to product development within the global cell and gene therapy market?

What are the regulations pertaining to the global cell and gene therapy market in different regions?

What are the initiatives implemented by different government bodies regulating the development and commercialization of cell and gene therapy products and associated platforms?

How has COVID-19 impacted the cell and gene therapy market?

How will the urgency of the pandemic influence the global cell and gene therapy market?

What are the leading companies dominating the global cell and gene therapy market?

What is the reimbursement scenario of the products offered in the global cell and gene therapy market?

Based on the product type, which therapy in the global cell and gene therapy market is anticipated to witness a massive rise in demand in the forecast period?

How is each segment of the global cell and gene therapy market expected to grow during the forecast period, and what is the revenue expected to be generated by each of the segments by the end of 2027?

Market Overview

Cell and gene therapy are overlapping fields of biomedical research having similar therapeutic goals, which target DNA or RNA inside or outside the body. Both therapies aim at modifying genetic material for treatment of a disease. Gene therapy uses genetic material, or DNA, to manipulate a patient's cells for the treatment of an inherited or acquired disease. Cell therapy is the introduction of new cells into a patient's body to grow, replace or repair damaged tissue to treat a disease. The cell and gene therapies are categorized into several therapeutic class, such as rare diseases, oncology, hematology, cardiovascular, ophthalmology, neurology, and others.

The global cell and gene therapy market was valued at $2,599.7 million in 2020, and it is expected to grow at an impressive double-digit rate of 33.82% and reach a value of $25,002.1 million in 2027.

The existing cell and gene therapy market is favored by multiple factors, which include increasing incidences of cancer and other chronic diseases, rising number of clinical trials, increasing funding and investments in the cell and gene therapy market, and favorable regulatory environment and FDA Approvals for cell and gene therapy products.

Within the research report, the market is segmented on the basis of product type (Yescarta, Provenge, Luxtura, Kymriah, Imlygic, Gintuit, MACI, Laviv, Gendicine, Oncorine, Neovasculgen, Strimvelis, Invossa, Zolgenesma, Tecartus, Liso-cel, Zyntelego, Others), therapeutic class type (Yescarta, Provenge, Luxtura, Kymriah, Imlygic, Gintuit, MACI, Laviv, Gendicine, Oncorine, Neovasculgen, Strimvelis, Invossa, Zolgenesma, Tecartus, Liso-cel, Zyntelego, Others), and region (North America, Europe, Asia Pacific, Latin America, and Rest-of-the-World). This segmentation highlights value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, and future opportunities, among other analyses, to detail the scope and provide a 360-coverage of the domain.

Competitive Landscape

The global cell and gene therapy market witnessed 14 mergers and acquisitions, 14 product launches and approvals, 13 joint ventures, and nine business expansions. 14 mergers and acquisitions, 14 product launches and approvals, 13 joint ventures, and nine business expansions.

Major players within the cell and gene therapy market are: Amgen Inc., bluebird bio, Inc., Castle Creek Pharmaceutical Holdings., Kite Pharma, Inc., Novartis AG, Orchard Therapeutics plc., Pfizer, Inc., Spark Therapeutics, Inc., Vericel Corporation, Dendreon Pharmaceuticals LLC., Human Stem Cells Institute, Kolon TissueGene, Inc., Organogenesis Holdings Inc., Pfizer, Inc., RENOVA THERAPEUTICS, Shanghai Sunway Biotech Co. Ltd., and Sibiono GeneTech Co. Ltd.

Product Code: BHP0729SC

1 Product Definition

1.1 Inclusion and Exclusion

2 Research Methodology

2.1 Primary Data Sources
2.2 Secondary Data Sources
2.3 Market Estimation Model
2.4 Selection Criteria for Company Profiles

3 Global Cell and Gene Therapy Market: Global Prospective

3.1 Introduction
3.2 Cell and Gene Therapy and Their Clinical Importance
3.3 Cell and Gene Therapy Development and Commercialization Landscape
3.4 Global Cell and Gene Therapy Market Size, 2020-2027
3.5 Role of Regulatory Bodies and Consortium in Cell and Gene Therapy
3.6 Reimbursement and Market Access
- 3.6.1 Reimbursement Scenario of Cell and Gene Therapy Market, by Country
  - 3.6.1.1 U.S.
  - 3.6.1.2 EU 5
    - 3.6.1.2.1 France
    - 3.6.1.2.2 Germany
    - 3.6.1.2.3 Italy
    - 3.6.1.2.4 Spain
    - 3.6.1.2.5 U.K.
3.7 Key Companies in Cell and Gene Therapy Market and their Contributions

4 Market Overview

4.1 Cell and Gene Therapy Industry
4.2 Key Successful Cell and Gene Therapy Commercialization
- 4.2.1 Regional Addressable Market and Growth Potential
4.3 North America
4.4 Europe
4.5 Asia-Pacific
4.6 Latin America
4.7 Rest-of-the-World

5 Impact of COVID-19 Pandemic on Global Cell and Gene Therapy Market

5.1 Disruption of Cell and Gene Therapy Market Due to COVID-19
5.2 COVID-19 Affecting Supply Chain of Cell and Gene Therapy Market
5.3 Interruption in Research and Clinical Development and Commercial Operation
- 5.3.1 Research and Clinical Development
- 5.3.2 Commercial Operation and Access
5.4 Navigating Crisis Recovery and Looking to the Future

6 Global Cell and Gene Therapy Market: Industry Analysis

6.1 Legal and Regulatory Framework and Requirements
- 6.1.1 Overview of Regulatory Pathway for Cell and Gene Therapy
  - 6.1.1.1 Fast Track Designation:
  - 6.1.1.2 Breakthrough Therapy:
  - 6.1.1.3 Accelerated Approval:
  - 6.1.1.4 Priority Review:
  - 6.1.1.5 Regenerative Medicine Advanced Therapy Designation:
- 6.1.2 Expedited Designation Vs. Traditional Approval Timelines:
- 6.1.3 Regulatory Challenges
- 6.1.4 Successful Regulatory Strategies

7 Patent Landscape

8 Cell and Gene Therapy Manufacturing

8.1 Viral Vector Manufacturing
- 8.1.1 Retrovirus
- 8.1.2 Lentivirus
- 8.1.3 AAV
- 8.1.4 Adenovirus
8.2 Upstream Manufacturing
- 8.2.1 Cost Consideration and Timelines
- 8.2.2 Process Design and Regulatory Burdens
- 8.2.3 Other Considerations
8.3 Downstream Manufacturing
- 8.3.1 Cost Considerations and Timelines
- 8.3.2 Challenges in Downstream
- 8.3.3 Scale-Up of Downstream from Research to Clinical Manufacturing
8.4 Non-Viral Vector Manufacturing
- 8.4.1 Non-Viral, Plasmid-Free Manufacturing
- 8.4.2 Plasmid
- 8.4.3 Naked DNA
- 8.4.4 Physical-Mediated Methods
8.5 Cell and Gene Therapy Manufacturing Capacity, by Company

9 Global Cell and Gene Therapy Market: Market Dynamics

9.1 Overview
9.2 Market Drivers
- 9.2.1 Increasing Incidences of Cancer and Other Chronic Diseases
- 9.2.2 High Number of Rare Diseases Across Globe
- 9.2.3 Rising Number of Clinical Trials
- 9.2.4 Increasing Funding and Investments in Cell and Gene Therapy Market
- 9.2.5 Favorable Regulatory Environment for Cell and Gene Therapy Products
9.3 Market Restrains
- 9.3.1 Lack of Reliable Vector Production for Cell and Gene Therapy
- 9.3.2 Complex Manufacturing and Distribution Setup
- 9.3.3 Tedious Process of Therapeutic Commercialization
9.4 Market Opportunities
- 9.4.1 Drug Approvals and Strong Pipeline of Cell and Gene Therapies
- 9.4.2 Increasing Number of Mergers and Acquisitions within the Cell and Gene Industry

10 Global Cell and Gene Therapy Market: Competitive Landscape

10.1 Key Strategies and Development
- 10.1.1 Product Offerings and Approvals
10.2 Synergistic Activities
10.3 Funding and Business Expansions
10.4 Mergers and Acquisitions
10.5 Market Share Analysis
10.6 Growth-Share Analysis (by Company), 2020

11 Global Cell and Gene Therapy Market (by Product)

11.1 Therapeutic Market
- 11.1.1 Yescarta
- 11.1.2 Provenge
- 11.1.3 Luxturna
- 11.1.4 Kymriah
- 11.1.5 Imlygic
- 11.1.6 Gintuit
- 11.1.7 MACI
- 11.1.8 Gendicine
- 11.1.9 Oncorine
- 11.1.10 Neovasculgen
- 11.1.11 Strimvelis
- 11.1.12 Invossa
- 11.1.13 Zolgensma
- 11.1.14 Tecartus
- 11.1.15 Liso-Cel
- 11.1.16 Zyntelego
- 11.1.17 Others
11.2 Pipeline Analysis
- 11.2.1 Phase 1
- 11.2.2 Phase 2
- 11.2.3 Phase 3
  - 11.2.3.1 SPK-8011
  - 11.2.3.2 OTL-103
  - 11.2.3.3 OTL-200
  - 11.2.3.4 OTL-101
  - 11.2.3.5 VM202
  - 11.2.3.6 GS010
  - 11.2.3.7 bb2121
  - 11.2.3.8 PTC-AADC
- 11.2.4 Pipeline Analysis - CAR-T Focused
- 11.2.5 Pipeline Analysis - CAR-NK Focused

12 Global Cell and Gene Therapy Market (by Therapeutic Class)

12.1 Overview
12.2 Rare Diseases
12.3 Oncology
12.4 Hematology
12.5 Cardiovascular
12.6 Ophthalmology
12.7 Neurology
12.8 Other Therapeutic Classes

13 Global Cell and Gene Therapy Market (by Region)

13.1 Overview
13.2 North America
- 13.2.1 U.S.
  - 13.2.1.1 Approved Products
  - 13.2.1.2 Competitive Landscape
  - 13.2.1.3 Market Size and Forecast
  - 13.2.1.4 Key Developments
- 13.2.2 Canada
  - 13.2.2.1 Approved Products
  - 13.2.2.2 Market Size and Forecast
  - 13.2.2.3 Key Developments
13.3 Europe
- 13.3.1 Europe Cell and Gene Therapy Market Dynamics
- 13.3.2 Germany
  - 13.3.2.1 Approved Products
  - 13.3.2.2 Market Size and Forecast
  - 13.3.2.3 Key Developments
- 13.3.3 France
  - 13.3.3.1 Approved Products
  - 13.3.3.2 Market Size and Forecast
  - 13.3.3.3 Key Developments
  - 13.3.3.4 Competitive Landscape
- 13.3.4 U.K.
  - 13.3.4.1 Approved Products
  - 13.3.4.2 Market Size and Forecast
  - 13.3.4.3 Competitive Landscape
- 13.3.5 Italy
  - 13.3.5.1 Approved Products
  - 13.3.5.2 Market Size and Forecast
  - 13.3.5.3 Key Developments
- 13.3.6 Spain
  - 13.3.6.1 Approved Products
  - 13.3.6.2 Market Size and Forecast
  - 13.3.6.3 Key Developments
  - 13.3.6.4 Competitive Landscape
- 13.3.7 The Netherlands
  - 13.3.7.1 Approved Products
  - 13.3.7.2 Market Size and Forecast
  - 13.3.7.3 Key Developments
  - 13.3.7.4 Competitive Landscape
- 13.3.8 Russia
  - 13.3.8.1 Approved Products
  - 13.3.8.2 Market Size and Forecast
  - 13.3.8.3 Competitive Landscape
- 13.3.9 Rest-of-Europe
  - 13.3.9.1 Market Size and Forecast
  - 13.3.9.2 Key Developments
13.4 Asia-Pacific (APAC)
- 13.4.1 Japan
  - 13.4.1.1 Approved Products
  - 13.4.1.2 Market Size and Forecast
  - 13.4.1.3 Key Developments
  - 13.4.1.4 Competitive Landscape
- 13.4.2 China
  - 13.4.2.1 Approved Products
  - 13.4.2.2 Market Size and Forecast
  - 13.4.2.3 Key Developments
  - 13.4.2.4 Competitive Landscape
- 13.4.3 Australia
  - 13.4.3.1 Approved Products
  - 13.4.3.2 Market Size and Forecast
  - 13.4.3.3 Key Developments
- 13.4.4 South Korea
  - 13.4.4.1 Approved Products
  - 13.4.4.2 Market Size and Forecast
  - 13.4.4.3 Key Developments
  - 13.4.4.4 Competitive Landscape
- 13.4.5 India
  - 13.4.5.1 Approved Products
  - 13.4.5.2 Market Size and Forecast
  - 13.4.5.3 Competitive Landscape
- 13.4.6 Singapore
  - 13.4.6.1 Approved Products
  - 13.4.6.2 Market Size and Forecast
  - 13.4.6.3 Key Developments
- 13.4.7 Rest-of-Asia-Pacific
  - 13.4.7.1 Market Size and Forecast
  - 13.4.7.2 Key Developments
13.5 Latin America
- 13.5.1 Brazil
  - 13.5.1.1 Market Size and Forecast
- 13.5.2 Mexico
  - 13.5.2.1 Market Size and Forecast
- 13.5.3 Rest-of-Latin America (RoLA)
  - 13.5.3.1 Market Size and Forecast
13.6 Rest-of-World
- 13.6.1 Market Size and Forecast

14 Company Profile

14.1 Amgen Inc.
- 14.1.1 Company Overview
- 14.1.2 Role of Amgen Inc. in the Global Cell and Gene Therapy Market
- 14.1.3 Financials
- 14.1.4 Key Insights About Financial Health of the Company
- 14.1.5 SWOT Analysis
14.2 bluebird bio, Inc.
- 14.2.1 Company Overview
- 14.2.2 Role of bluebird bio, Inc. in the Global Cell and Gene Therapy Market
- 14.2.3 Financials
- 14.2.4 Key Insights About Financial Health of the Company
- 14.2.5 SWOT Analysis
14.3 Dendreon Pharmaceuticals LLC.
- 14.3.1 Company Overview
- 14.3.2 Role of Dendreon Pharmaceuticals LLC. in the Global Cell and Gene Therapy Market
- 14.3.3 SWOT Analysis
14.4 Castle Creek Pharmaceutical Holdings
- 14.4.1 Company Overview
- 14.4.2 Role of Castle Creek Pharmaceutical Holdings in the Global Cell and Gene Therapy Market
- 14.4.3 SWOT Analysis
14.5 Human Stem Cells Institute
- 14.5.1 Company Overview
- 14.5.2 Role of Human Stem Global Cell and Gene Therapy Cell Market
- 14.5.3 SWOT Analysis
14.6 Kite Pharma, Inc.
- 14.6.1 Company Overview
- 14.6.2 Role of Kite Pharma, Inc. in the Global Cell and Gene Therapy Market
- 14.6.3 Financials
- 14.6.4 Key Insights About Financial Health of the Company
- 14.6.5 SWOT Analysis
14.7 Kolon TissueGene, Inc.
- 14.7.1 Company Overview
- 14.7.2 Role of Kolon TissueGene, Inc. in the Global Cell and Gene Therapy Market
- 14.7.3 SWOT Analysis
14.8 Novartis AG
- 14.8.1 Company Overview
- 14.8.2 Role of Novartis AG in the Global Cell and Gene Therapy Market
- 14.8.3 Financials
- 14.8.4 Key Insights About Financial Health of the Company
- 14.8.5 SWOT Analysis
14.9 Orchard Therapeutics plc.
- 14.9.1 Company Overview
- 14.9.2 Role of Orchard Therapeutics plc. in the Global Cell and Gene Therapy Market
- 14.9.3 Financials
- 14.9.4 SWOT Analysis
14.10 Organogenesis Holdings Inc.
- 14.10.1 Company Overview
- 14.10.2 Role of Organogenesis Holdings Inc. in the Global Cell and Gene Therapy Market
- 14.10.3 Financials
- 14.10.4 Key Insights About Financial Health of the Company
- 14.10.5 SWOT Analysis
14.11 Pfizer, Inc.
- 14.11.1 Company Overview
- 14.11.2 Role of Pfizer, Inc. in the Global Cell and Gene Therapy Market
- 14.11.3 Financials
- 14.11.4 Key Insights About Financial Health of the Company
- 14.11.5 SWOT Analysis
14.12 RENOVA THERAPEUTICS
- 14.12.1 Company Overview
- 14.12.2 Role of RENOVA THERAPEUTICS in the Global Cell and Gene Therapy Market
- 14.12.3 SWOT Analysis
14.13 Shanghai Sunway Biotech Co., Ltd.,
- 14.13.1 Company Overview
- 14.13.2 Role of Shanghai Sunway Biotech Co., Ltd., in the Global Cell and Gene Therapy Market
- 14.13.3 SWOT Analysis
14.14 Sibiono GeneTech Co. Ltd.,
- 14.14.1 Company Overview
- 14.14.2 Role of Sibiono GeneTech Co. Ltd., in the Global Cell and Gene Therapy
- 14.14.3 SWOT Analysis
14.15 Spark Therapeutics, Inc.
- 14.15.1 Company Overview
- 14.15.2 Role of Spark Therapeutics, Inc. in the Global Cell and Gene Test Market
- 14.15.3 Financials
- 14.15.4 Key Insights About Financial Health of the Company
- 14.15.5 SWOT Analysis
14.16 Vericel Corporation
- 14.16.1 Company Overview
- 14.16.2 Role of Vericel Corporation in the Global Cell and Gene Therapy Market
- 14.16.3 Financials
- 14.16.4 Key Insights About Financial Health of the Company
- 14.16.5 SWOT Analysis

List of Tables

Table 3.1: Approved Gene Therapies Worldwide
Table 3.2: Key Companies in Cell and Gene Therapy Market, 2020
Table 4.1: Key Products of Cell and Gene Therapy Market
Table 8.1: Key Viral Vectors
Table 8.2: Cell and Gene Therapy Manufacturing Capacity (by Company)
Table 9.1: Number of Clinical Trials for Cell and Gene Therapy, 2020
Table 11.1: List of key Cell/Gene Therapy Products with Marketing Authorization (MA)
Table 11.2: Key Cell and Gene Therapy Drugs in Phase 3, 2020
Table 12.1: List of Cell and Gene Therapy Products with Marketing Authorization in the European Union by EMA

List of Figures

Figure 1: Cell and Gene Therapy Funding (2019 and 2020-H1)
Figure 2: Global Cell and Gene Therapy Market, 2020-2027
Figure 3: Market Drivers, Opportunities, and Restraints
Figure 4: Share of Key Developments and Strategies, January 2016-January 2021
Figure 5: Global Cell and Gene Therapy Market Share (Product Type), 2020-2027
Figure 6: Global Cell and Gene Therapy Market Share (by Therapeutic Class), 2020-2027
Figure 7: Global Cell and Gene Therapy Market (by Region)
Figure 1.1: Definitions of Cell and Gene Therapies
Figure 2.1: Global Cell and Gene Therapy Market Research Methodology
Figure 2.2: Primary Research Methodology
Figure 2.3: Global Cell and Gene Therapy Market Research Methodology Approach
Figure 2.4: Total Number of Companies Profiled
Figure 3.1: Clinical Trials by Therapeutic Category, Regenerative Medicines and Advanced Therapies, 2020
Figure 3.2: Global Cell and Gene Therapy Market Size, 2020-2027
Figure 3.3: Factors Involved in Payer Decision Flow, Process Considerations and Stakeholder Drivers in Reimbursement in U.S.
Figure 3.4: Emerging Payment Models for Cell and Gene Therapies in Europe
Figure 4.1: Addressable Market Size of Commercialized Products, 2020
Figure 4.2: Global Cell and Gene Therapy Market, 2020-2027
Figure 4.3: North America Cell and Gene Therapy Addressable Market, 2020 Vs 2027
Figure 4.4: Europe Cell and Gene Therapy Addressable Market, 2020 Vs 2027
Figure 4.5: Asia-Pacific Cell and Gene Therapy Addressable Market, 2020 Vs 2027
Figure 4.6: Latin America Cell and Gene Therapy Addressable Market 2020 Vs 2027
Figure 5.1: Number of Cancer Cases Diagnosed in the Netherlands (January 3, 2020, to April 12, 2020)
Figure 5.2: Pre-COVID-19 and Post-COVID-19 Scenario of Global Cell and Gene Therapy Market, 2020-2025
Figure 5.3: Areas of Disruption in Clinical Development
Figure 5.4: Measure to Navigate Crisis Recovery
Figure 6.1: Expedited Approval Designations for Cell and Gene Therapies
Figure 7.1: Number of Patents (by Year), 2016-2020
Figure 7.2: Share of Patents (by Country), 2016-2021
Figure 8.1: Steps Involved in Bioprocessing
Figure 8.2: Typical Production Methods of Viral Vectors
Figure 8.3: Typical Production Method of Plasmid Vectors
Figure 9.1: Impact Analysis of Market Dynamics
Figure 9.2: Rising Incidences of Cancer (2015 and 2018)
Figure 9.3: Prevalence of Rare Diseases
Figure 9.4: Deal Value of Mergers and Acquisitions (2016-2019)
Figure 10.1: Share of Key Developments and Strategies, January 2016- January 2021
Figure 10.2: Share of Product Offerings and Approvals, January 2016-January 2021
Figure 10.3: Share of Synergistic Activities, January 2016-January 2021
Figure 10.4: Share of Funding and Expansions, January 2016-January 2021
Figure 10.5: Share of Mergers and Acquisitions, January 2016-January 2021
Figure 10.6: Market Share Analysis: Global Cell and Gene Therapy Market, 2020
Figure 10.7: Growth-Share Matrix for Global Cell and Gene Therapy Market (by Company), 2020
Figure 11.1: Global Cell and Gene Therapy Market (by Therapeutic Drugs), 2020-2027
Figure 11.2: Global Revenue for Yescarta, 2020-2027
Figure 11.3: Global Revenue for Provenge, 2020-2027
Figure 11.4: Global Revenue for Luxturna, 2020-2027
Figure 11.5: Global Revenue for Kymriah, 2020-2027
Figure 11.6: Global Revenue for Imlygic, 2020-2027
Figure 11.7: Global Revenue for MACI, 2020-2027
Figure 11.8: Global Revenue for Gendicine, 2020-2027
Figure 11.9: Global Revenue for Oncorine, 2020-2027
Figure 11.10: Global Revenue for Neovasculogen, 2020-2027
Figure 11.11: Global Revenue for Strimvelis, 2020-2027
Figure 11.12: Global Revenue for Invossa, 2020-2027
Figure 11.13: Global Revenue for Zolgensma, 2020-2027
Figure 11.14: Global Revenue for Tecartus, 2020-2027
Figure 11.15: Global Revenue for Other Drugs, 2020-2027
Figure 11.16: Global Revenue for Other Drugs, 2020-2027
Figure 11.17: Global Revenue for Other Drugs, 2020-2027
Figure 11.18: Cell and Gene Therapy Medicines in Development by Disease, 2018
Figure 11.19: Number of Phase 1 Clinical Trials for Cell and Gene Therapy, 2018-2020
Figure 11.20: Number of Phase 2 Clinical Trials for Cell and Gene Therapy, 2018-2020
Figure 11.21: Global Cell and Gene Therapy Market, by Late Phase, 2021-2027
Figure 11.22: Global Revenue for SPK-8011, 2020-2027
Figure 11.23: Global Revenue for OTL-103, 2021-2027
Figure 11.24: Global Revenue for OTL-200, 2020-2027
Figure 11.25: Global Revenue for OTL-101, 2021-2027
Figure 11.26: Global Revenue for VM 202, 2021-2027
Figure 11.27: Global Revenue for GS010, 2021-2027
Figure 11.28: Global Revenue for bb2121, 2021-2027
Figure 11.29: Global Revenue for PTC-AADC, 2021-2027
Figure 11.30: Pipeline For CAR-T Therapies (2020)
Figure 12.1: Global Cell and Gene Therapy Market (Rare Diseases), 2020-2027
Figure 12.2: Global Cell and Gene Therapy Market (Oncology), 2020-2027
Figure 12.3: Global Cell and Gene Therapy Market (Hematology), 2020-2027
Figure 12.4: Global Cell and Gene Therapy Market (Cardiovascular Disease), 2020-2027
Figure 12.5: Global Cell and Gene Therapy Market (Ophthalmology), 2020-2027
Figure 12.6: Global Cell and Gene Therapy Market (Neurology), 2020-2027
Figure 12.7: Global Cell and Gene Therapy Market (Other Therapeutic Class), 2020-2027
Figure 12.8: Global Cell and Gene Therapy Market (by Region)
Figure 12.9: North America Global Cell and Gene Therapy Market, 2020-2027
Figure 12.10: North America: Market Dynamics
Figure 12.11: U.S. Cell and Gene Therapy Market, 2020-2027
Figure 12.12: Canada Cell and Gene Therapy Market, 2020-2027
Figure 12.13: Europe Cell and Gene Therapy Market, 2020-2027
Figure 12.14: Europe: Market Dynamics
Figure 12.15: Germany Cell and Gene Therapy Market, 2020-2027
Figure 12.16: France Cell and Gene Therapy Market, 2020-2027
Figure 12.17: U.K. Cell and Gene Therapy Market, 2020-2027
Figure 12.18: Italy Cell and Gene Therapy Market, 2020-2027
Figure 12.19: Spain Cell and Gene Therapy Market, 2020-2027
Figure 12.20 Netherlands Cell and Gene Therapy Market, 2020-2027
Figure 12.21: Russia Cell and Gene Therapy Market, 2020-2027
Figure 12.22: Rest-of-Europe Cell and Gene Therapy Market, 2020-2027
Figure 12.23: Asia-Pacific Cell and Gene Therapy Market, 2020-2027
Figure 12.24: Asia-Pacific Market Dynamics
Figure 12.25: Japan Cell and Gene Therapy Market, 2020-2027
Figure 12.26: China Cell and Gene Therapy Market, 2020-2027
Figure 12.27: Australia Cell and Gene Therapy Market, 2020-2027
Figure 12.28: South Korea Cell and Gene Therapy Market, 2020-2027
Figure 12.29: India Cell and Gene Therapy Market, 2020-2027
Figure 12.30: Singapore Cell and Gene Therapy Market, 2020-2027
Figure 12.31: Rest-of-Asia-Pacific Cell and Gene Therapy Market, 2020-2027
Figure 12.32: Latin America Cell and Gene Therapy Market, 2020-2027
Figure 12.33: Latin America: Market Dynamics
Figure 12.34: Brazil Cell and Gene Therapy Market, 2020-2027
Figure 12.35: Mexico Cell and Gene Therapy Market, 2020-2027
Figure 12.36: Rest-of-Latin America Cell and Gene Therapy Market, 2020-2027
Figure 12.37: Rest-of-World Cell and Gene Therapy Market, 2020-2027
Figure 13.1: Amgen Inc.: Overall Product Portfolio
Figure 13.2: Amgen Inc.: Pipeline Product Portfolio
Figure 13.3: Amgen Inc.: Overall Financials, 2017-2019
Figure 13.4: Amgen Inc.: Revenue (by Region), 2017-2019
Figure 13.5: Amgen Inc.: R&D Expenditure, 2017-2019
Figure 13.6: Amgen Inc.: SWOT Analysis
Figure 13.7: Pipeline Product Portfolio: bluebird bio, Inc.
Figure 13.8: bluebird bio, Inc.: Overall Financials, 2017-2019
Figure 13.9: bluebird bio, Inc.: R&D Expenditure, 2017-2019
Figure 13.10: bluebird bio, Inc.: SWOT Analysis
Figure 13.11: Dendreon Pharmaceuticals LLC: Product Portfolio
Figure 13.12: Dendreon Pharmaceuticals LLC.: SWOT Analysis
Figure 13.13: Castle Creek Pharmaceutical Holdings: Overall Product Portfolio
Figure 13.14: Castle Creek Pharmaceutical Holdings : Pipeline Product Portfolio
Figure 13.15: Castle Creek Pharmaceutical: SWOT Analysis
Figure 13.16: Human Stem Cell Institute: Overall Product Portfolio
Figure 13.17: Human Stem Cell Institute: SWOT Analysis
Figure 13.18: Kite Pharma, Inc.: Overall Product Portfolio
Figure 13.19: Kite Pharma, Inc.: Pipeline Product Portfolio
Figure 13.20: Kite Pharma, Inc.: Overall Financials, 2016-2018
Figure 13.21: Kite Pharma, Inc.: R&D Expenditure, 2016-2018
Figure 13.22: Kite Pharma, Inc.: SWOT Analysis
Figure 13.23: Kolon TissueGene, Inc.: Pipeline Product Portfolio
Figure 13.24: Kolon TissueGene, Inc.: SWOT Analysis
Figure 13.25: Novartis AG: Overall Product Portfolio
Figure 13.26: Novartis AG: Pipeline Product Portfolio
Figure 13.27: Novartis AG: Overall Financials, 2017-2019
Figure 13.28: Novartis AG: Revenue (by Business Segment), 2017-2019
Figure 13.29: Novartis AG: Net Revenue (by Region), 2017-2019
Figure 13.30: Novartis AG: R& D Expense, 2017-2019
Figure 13.31: Novartis AG: SWOT Analysis
Figure 13.32: Orchard Therapeutics plc.: Pipeline Product Portfolio
Figure 13.33: Orchard Therapeutics plc.: Overall Financials, 2017-2019
Figure 13.34: Orchard Therapeutics plc: SWOT Analysis
Figure 13.35: Organogenesis Holdings Inc.: Overall Product Portfolio
Figure 13.36: Organogenesis Holdings Inc.: Overall Financials, 2017-2019
Figure 13.37: Organogenesis Holdings Inc.: R&D Expenditure, 2017-2019
Figure 13.38: Organogenesis Holdings Inc.: SWOT Analysis
Figure 13.39: Pfizer, Inc.: Overall Product Portfolio
Figure 13.40: Pfizer, Inc.: Pipeline Product Portfolio
Figure 13.41: Pfizer, Inc.: Overall Financials, 2017-2019
Figure 13.42: Pfizer, Inc.: Revenue (by Region), 2017-2019
Figure 13.43: Pfizer, Inc.: R&D Expenditure, 2017-2019
Figure 13.44: Pfizer, Inc.: SWOT Analysis
Figure 13.45: RENOVA THERAPEUTICS: Pipeline Product Portfolio
Figure 13.46: RENOVA THERAPEUTICS: SWOT Analysis
Figure 13.47: Product Portfolio: Shanghai Sunway Biotech Co., Ltd.,
Figure 13.48: Shanghai Sunway Biotech Co., Ltd.: SWOT Analysis
Figure 13.49: Sibiono GeneTech Co. Ltd.: Overall Product Portfolio
Figure 13.50: Sibiono GeneTech Co. Ltd.: SWOT Analysis
Figure 13.51: Spark Therapeutics, Inc.: Overall Product Portfolio
Figure 13.52: Spark Therapeutics, Inc.: Pipeline Product Portfolio
Figure 13.53: Spark Therapeutics, Inc.: Overall Financials, 2017-2019
Figure 13.54: Spark Therapeutics, Inc.: R&D Expenditure, 2017-2019
Figure 13.55: Spark Therapeutics, Inc.: SWOT Analysis
Figure 13.56: Vericel Corporation: Overall Product Portfolio
Figure 13.57: Vericel Corporation: Overall Financials, 2017-2019
Figure 13.58: Vericel Corporation: Revenue (by Product), 2017-2019
Figure 13.59: Vericel Corporation: R&D Expenditure (2017-2019)
Figure 13.60: Vericel Corporation: SWOT Analysis